All News

Article

Rheumatic Events With Checkpoint Inhibitors: Tumor Type Matters

MedPage Today

Among the factors that were associated with an increased risk for the development of rheumatic immune-related adverse events following cancer treatment with immune checkpoint inhibitors (ICIs) was the type of malignancy involved, a large case-control study found.

Article

Passive Smoke Exposure and Rheumatoid Risk

Jack Cush, MD

A current report in Arthritis & Rheumatology examined the Nurses Health Study II data set and shows that parental smoking, and passive exposure to children, can later lead to an increased risk of adult-onset incident seropositive rheumatoid arthritis (RA).

Leonard Calabrese Tweet
LCalabreseDO
Given the DELTA breakthrough surge how do you feel about live medical meetings (n> 50) in the next 6 weeks @Janetbirdope @KDAO2011 @psufka @AngusWorthing @RonanTKavanagh @RheumNow @MattieRheumMD @rheum_cat @jeffsparks @hausmannMD @CCalabreseDO @DrSwamyV
Dr. John Cush Tweet
RheumNow
Among pregnant women, receipt of the BNT162b2 vaccine was associated with a 78% lower risk of incident SARS-CoV-2 infection. Cohort study tincluded 15 060 pregnant women in Israel. No adverse pregnancy outcome difference in Vax Pts https://t.co/jXUjaKIfUV
Dr. John Cush Tweet
RheumNow
Novel tech Sorrento's SOFUSA system, in Phase Ib trial, etanercept given by transdermal nanotopography microneedles to deliver higher concentration of drugs to lymphatic system. An enbrel refractory pt treated & showed 34% improved DAS scores https://t.co/S79HUBT7rE
Dr. John Cush Tweet
RheumNow
CDC: LA county breakthrough COVID infections: In 43,000 new COVID, 10,895, or 25.3%, occurred in fully vaccinated persons, 1,431, or 3.3%, were in partially vaccinated persons, and 30,801, or 71.4%, were in unvaccinated individuals. https://t.co/gbgaV7THch
Dr. John Cush Tweet
RheumNow
Safety study of 97 AAV (72 GPA, 25 MPA) pts Rx with Rituxan, median 8 infusions, followed median 3.9 yrs (0.05–4.32). Serious Risks (per 100 Pt-Yrs): serious infections 7.11, cardiac events 5.0, & vascular events 2.37. No deaths related to RTX. https://t.co/WLMQoq79gd
Dr. John Cush Tweet
RheumNow
Psoriasis Prevalence in adults in the United States is 3.0%, indicating that more than 7.5 million adults 20 years or older have psoriasis. Most common in non-Hispanic White individuals; prevalence has not significantly changed since 2003. https://t.co/3yrlPu1GGi
Dr. John Cush Tweet
RheumNow
European Commission has approved tofacitinib (Xeljanz) to treat active polyarticular juvenile idiopathic arthritis & juvenile psoriatic arthritis (PsA) > 2yrs old, not responding to DMARDs (as tablet & new oral solution (weight-based dosing) https://t.co/FyqZI0qsYa
Dr. John Cush Tweet
RheumNow
Breakthrough infections: As of Aug. 9, almost 74% of the 8,054 vaccinated people that were hospitalized with COVID-19 were above the age of 65, according to the U.S. Centers for Disease Control and Prevention. ~20% of those cases ended in deaths https://t.co/jaSmKv5pPS
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×